Drugs.com - Monthly Update June 2026

Drugs.com - Monthly Update June 2026

This month, we're exploring advances across multiple therapeutic areas. We cover Lumvoa for thyroid eye disease, Utebzi for complicated urinary tract infections, and Tregzi for blood cancers. * Lumvoa [https://www.drugs.com/lumvoa.html] (veligrotug-vvze): Approved for thyroid eye disease, Lumvoa is an IGF-1R inhibitor that offers significant improvements in TED symptoms, with notable early effectiveness. * Utebzi [https://www.drugs.com/utebzi.html] (tebipenem pivoxil): The first oral carbapenem approved in the U.S., providing a new option for treating complicated urinary tract infections, demonstrating efficacy comparable to intravenous options. * Tregzi [https://www.drugs.com/tregzi.html] (Orca-T or allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq): A precision-engineered cell therapy for use in donor stem cell transplantation, to help rebuild the blood and immune system, and to improve chronic graft-versus-host disease (GVHD)-free survival, in adults with blood cancers (hematological malignancies). Chapters: * (00:21) - Intro * (00:41) - Lumvoa * (01:42) - Utebzi * (02:42) - Tregzi * (03:21) - Outro Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], YouTube [https://www.youtube.com/user/drugscom] * Sign up to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]

Drugs.com - Monthly Update May 2026

In this May 2026 Monthly Update edition, we cover several new FDA approvals and a major prescription-to-OTC switch expanding therapeutic options. * Veppanu [https://www.drugs.com/history/veppanu.html] (vepdegestrant): The first PROTAC (PROteolysis TArgeting Chimera) therapy to be approved for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer based on strong progression-free survival clinical data. * Trimbow [https://www.drugs.com/history/trimbow.html] (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate): A triple-combination inhalation aerosol approved for the long-term maintenance treatment of adult asthma. * Xocova [https://www.drugs.com/history/xocova.html] (ensitrelvir): The first oral antiviral tablet indicated for post-exposure prophylaxis (PEP) to prevent COVID-19 following exposure. * Baxfendy [https://www.drugs.com/history/baxfendy.html] (baxdrostat): A first-in-class oral aldosterone synthase inhibitor approved to treat uncontrolled hypertension in combination with other agents. * Differin Epiduo Acne Gel [https://www.drugs.com/history/differin-epiduo-acne-gel.html] (adapalene/benzoyl peroxide): A prescription combination acne treatment newly approved for over-the-counter (OTC) use. * Zaynich [https://www.drugs.com/history/zaynich.html] (cefepime/zidebactam): An intravenous antibiotic approved for adults suffering from complicated urinary tract infections and pyelonephritis. * Immgolis [https://www.drugs.com/history/immgolis.html] (golimumab-sldi): The first interchangeable biosimilar to Simponi approved for adult rheumatoid arthritis and ulcerative colitis. Chapters: * (00:20) - Intro * (00:58) - Veppanu * (01:58) - Trimbow * (03:13) - Xocova * (04:28) - Zaynich * (05:31) - Baxfendy * (06:28) - Differin Epiduo Acne Gel * (07:28) - Immgolis * (08:06) - Outro Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], YouTube [https://www.youtube.com/user/drugscom] * Sign up to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]

Drugs.com - Monthly Update April 2026

In this April 2026 Monthly Update edition, we highlight several FDA approvals that introduce first-of-their-kind therapies and improve access to existing treatments. * Foundayo (orforglipron): A first-of-its-kind small-molecule oral GLP-1 receptor agonist for chronic weight management without strict food or water requirements. * Otarmeni (lunsotogene parvec-cwha): An innovative gene therapy for pediatric and adult patients with OTOF-related genetic hearing loss. * Idvynso (doravirine and islatravir): A new once-daily, two-drug single-tablet regimen for adults with HIV-1 who are virologically suppressed. * Langlara (insulin glargine-aldy): A interchangeable biosimilar to Lantus for the treatment of type 1 and type 2 diabetes. Chapters: * (00:21) - Intro * (01:05) - Foundayo * (01:59) - Otarmeni * (02:55) - Idvynso * (03:50) - Langlara * (04:42) - Outro Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], YouTube [https://www.youtube.com/user/drugscom] * Sign up to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]

Drugs.com - Monthly Update March 2026

In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes.  Wegovy HD [https://www.drugs.com/mtm/wegovy-hd-pen.html] (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials. Icotyde [https://www.drugs.com/icotyde.html] (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment choice. Sotyktu [https://www.drugs.com/sotyktu.html] (deucravacitinib): An oral TYK2 inhibitor now approved for treating active psoriatic arthritis, addressing inflammation with a convenient dosing regimen. Awiqli [https://www.drugs.com/awiqli.html] (insulin isodec): The first once-weekly basal insulin for adults with type 2 diabetes. Chapters: * (00:21) - Intro * (01:00) - Wegovy HD * (02:10) - Icotyde * (03:12) - Sotyktu * (03:53) - Awiqli * (04:32) - Outro Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], Youtube [https://www.youtube.com/user/drugscom] * Sign up to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]

Drugs.com - Monthly Update February 2026

In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and the monthly Rybrevant Faspro injection for advanced NSCLC. * Zepbound KwikPen [https://www.drugs.com/zepbound.html] (tirzepatide): A new multidose Zepbound pen supplying 4 fixed weekly doses in one pen  * Ozempic pill [https://www.drugs.com/ozempic.html] (semaglutide): Discover the upcoming once-daily oral option for adults with type 2 diabetes to manage blood sugar and cardiovascular risks. * Rybrevant Faspro [https://www.drugs.com/rybrevant-faspro.html] (amivantamab and hyaluronidase-lpuj): Explore the benefits of a simplified, monthly injectable regimen for EGFR-mutated NSCLC. * Dupixent [https://www.drugs.com/dupixent.html] (dupilumab): The first approved therapy for allergic fungal rhinosinusitis, reducing the need for systemic steroids. * Vybrique [https://www.drugs.com/vybrique.html] (sildenafil): A new oral film formulation of sildenafil for erectile dysfunction. * Calquence [https://www.drugs.com/calquence.html] + Venetoclax [https://www.drugs.com/venetoclax.html] (acalabrutinib combination): This new all-oral regimen provides a targeted therapy for CLL, improving patient outcomes with a non-chemo approach. Chapters: * (00:00) - Intro * (00:20) - Overview Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], Youtube [https://www.youtube.com/user/drugscom] * Signup to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]